Aerosol vaccines for tuberculosis: a fine line between protection and pathology.
Pulmonary delivery of vaccines against airborne infection is being investigated worldwide, but there is limited effort directed at developing inhaled vaccines for tuberculosis (TB). This review addresses some of the challenges confronting vaccine development for TB and attempts to link these challenges to the promises of mucosal immunity offered by pulmonary delivery. There are several approaches working toward this goal including subunit vaccines, recombinant strains, a novel vaccine strain Mycobacterium w, and DNA vaccine approaches. While it is clear that lung-resident adaptive immunity is an attainable goal, vaccine platforms must ensure that damage to the lung is limited during both vaccination and when memory cells respond to pathogenic infection.
Aeras Global TB Vaccine Foundation, Vaccine Assessment, 1405 Research Boulevard, Suite 300, Rockville, MD 20850, USA. dhokey@aeras.org
David A
DA
Hokey
Amit
A
Misra
D000280:Administration, Inhalation; D000281:Administration, Intranasal; D000336:Aerosols; D005260:Female; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000276:immunology; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000276:immunology; D012307:Risk Factors; D032581:Tuberculosis Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000276:immunology / Q000517:prevention & control*
D000336:Aerosols; D032581:Tuberculosis Vaccines